1
|
Beller P, Fink P, Wolf F, Männle D, Helmle I, Kuttenlochner W, Unterfrauner D, Engelbrecht A, Staudt ND, Kulik A, Groll M, Gross H, Kaysser L. Characterization of the cystargolide biosynthetic gene cluster and functional analysis of the methyltransferase CysG. J Biol Chem 2024; 300:105507. [PMID: 38029966 PMCID: PMC10776993 DOI: 10.1016/j.jbc.2023.105507] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/24/2023] [Revised: 11/17/2023] [Accepted: 11/21/2023] [Indexed: 12/01/2023] Open
Abstract
Cystargolides are natural products originally isolated from Kitasatospora cystarginea NRRL B16505 as inhibitors of the proteasome. They are composed of a dipeptide backbone linked to a β-lactone warhead. Recently, we identified the cystargolide biosynthetic gene cluster, but systematic genetic analyses had not been carried out because of the lack of a heterologous expression system. Here, we report the discovery of a homologous cystargolide biosynthetic pathway in Streptomyces durhamensis NRRL-B3309 by genome mining. The gene cluster was cloned via transformation-associated recombination and heterologously expressed in Streptomyces coelicolor M512. We demonstrate that it contains all genes necessary for the production of cystargolide A and B. Single gene deletion experiments reveal that only five of the eight genes from the initially proposed gene cluster are essential for cystargolide synthesis. Additional insights into the cystargolide pathway could be obtained from in vitro assays with CysG and chemical complementation of the respective gene knockout. This could be further supported by the in vitro investigation of the CysG homolog BelI from the belactosin biosynthetic gene cluster. Thereby, we confirm that CysG and BelI catalyze a cryptic SAM-dependent transfer of a methyl group that is critical for the construction of the cystargolide and belactosin β-lactone warheads.
Collapse
Affiliation(s)
- Patrick Beller
- Department of Pharmaceutical Biology, Pharmaceutical Institute, University of Tübingen, Tübingen, Germany
| | - Phillipp Fink
- Department of Pharmaceutical Biology, Pharmaceutical Institute, University of Tübingen, Tübingen, Germany
| | - Felix Wolf
- Department of Pharmaceutical Biology, Pharmaceutical Institute, University of Tübingen, Tübingen, Germany
| | - Daniel Männle
- Department of Pharmaceutical Biology, Pharmaceutical Institute, University of Tübingen, Tübingen, Germany
| | - Irina Helmle
- Department of Pharmaceutical Biology, Pharmaceutical Institute, University of Tübingen, Tübingen, Germany
| | - Wolfgang Kuttenlochner
- Department of Bioscience, Center for Protein Assemblies (CPA), TUM School of Natural Sciences, Technical University of Munich, Garching, Germany
| | - Daniel Unterfrauner
- Department of Pharmaceutical Biology, Pharmaceutical Institute, University of Tübingen, Tübingen, Germany
| | - Alicia Engelbrecht
- Department of Pharmaceutical Biology, Pharmaceutical Institute, University of Tübingen, Tübingen, Germany
| | - Nicole D Staudt
- Department of Pharmaceutical Biology, Pharmaceutical Institute, University of Tübingen, Tübingen, Germany
| | - Andreas Kulik
- Interfaculty Institute for Microbiology and Infection Medicine Tübingen (IMIT), Microbial Bioactive Compounds, University of Tübingen, Tübingen, Germany
| | - Michael Groll
- Department of Bioscience, Center for Protein Assemblies (CPA), TUM School of Natural Sciences, Technical University of Munich, Garching, Germany
| | - Harald Gross
- Department of Pharmaceutical Biology, Pharmaceutical Institute, University of Tübingen, Tübingen, Germany
| | - Leonard Kaysser
- Department of Pharmaceutical Biology, Institute for Drug Discovery, University of Leipzig, Leipzig, Germany.
| |
Collapse
|
2
|
Ushimaru R. Unusual Enzymatic C-C Bond Formation and Cleavage Reactions during Natural Product Biosynthesis. Chem Pharm Bull (Tokyo) 2024; 72:241-247. [PMID: 38432903 DOI: 10.1248/cpb.c23-00889] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/05/2024]
Abstract
Natural products from plants and microorganisms provide a valuable reservoir of pharmaceutical compounds. C-C bond formation and cleavage are crucial events during natural product biosynthesis, playing pivotal roles in generating diverse and intricate chemical structures that are essential for biological functions. This review summarizes our recent findings regarding biosynthetic enzymes that catalyze unconventional C-C bond formation and cleavage reactions during natural product biosynthesis.
Collapse
Affiliation(s)
- Richiro Ushimaru
- Graduate School of Pharmaceutical Sciences, The University of Tokyo
- Collaborative Research Institute for Innovative Microbiology, The University of Tokyo
| |
Collapse
|
3
|
Ushimaru R. Three-membered ring formation catalyzed by α-ketoglutarate-dependent nonheme iron enzymes. J Nat Med 2024; 78:21-32. [PMID: 37980694 PMCID: PMC10764440 DOI: 10.1007/s11418-023-01760-4] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/16/2023] [Accepted: 10/25/2023] [Indexed: 11/21/2023]
Abstract
Epoxides, aziridines, and cyclopropanes are found in various medicinal natural products, including polyketides, terpenes, peptides, and alkaloids. Many classes of biosynthetic enzymes are involved in constructing these ring structures during their biosynthesis. This review summarizes our current knowledge regarding how α-ketoglutarate-dependent nonheme iron enzymes catalyze the formation of epoxides, aziridines, and cyclopropanes in nature, with a focus on enzyme mechanisms.
Collapse
Affiliation(s)
- Richiro Ushimaru
- Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo, 113-0033, Japan.
- Collaborative Research Institute for Innovative Microbiology, The University of Tokyo, Tokyo, 113-8657, Japan.
| |
Collapse
|
4
|
Ushimaru R, Abe I. Unusual Dioxygen-Dependent Reactions Catalyzed by Nonheme Iron Enzymes in Natural Product Biosynthesis. ACS Catal 2022. [DOI: 10.1021/acscatal.2c05247] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Affiliation(s)
- Richiro Ushimaru
- Graduate School of Pharmaceutical Sciences, The University of Tokyo, Bunkyo-ku, Tokyo 113-0033, Japan
- Collaborative Research Institute for Innovative Microbiology, The University of Tokyo, Bunkyo-ku, Tokyo 113-0033, Japan
- ACT-X, Japan Science and Technology Agency (JST), Honcho, Kawaguchi, Saitama 332-0012, Japan
| | - Ikuro Abe
- Graduate School of Pharmaceutical Sciences, The University of Tokyo, Bunkyo-ku, Tokyo 113-0033, Japan
- Collaborative Research Institute for Innovative Microbiology, The University of Tokyo, Bunkyo-ku, Tokyo 113-0033, Japan
| |
Collapse
|
5
|
Ferrari V, Stroobant V, Abi Habib J, Naulaerts S, Van den Eynde BJ, Vigneron N. New Insights into the Mechanisms of Proteasome-Mediated Peptide Splicing Learned from Comparing Splicing Efficiency by Different Proteasome Subtypes. JOURNAL OF IMMUNOLOGY (BALTIMORE, MD. : 1950) 2022; 208:2817-2828. [PMID: 35688464 DOI: 10.4049/jimmunol.2101198] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/22/2021] [Accepted: 04/03/2022] [Indexed: 06/15/2023]
Abstract
By tying peptide fragments originally distant in parental proteins, the proteasome can generate spliced peptides that are recognized by CTL. This occurs by transpeptidation involving a peptide-acyl-enzyme intermediate and another peptide fragment present in the catalytic chamber. Four main subtypes of proteasomes exist: the standard proteasome (SP), the immunoproteasome, and intermediate proteasomes β1-β2-β5i (single intermediate proteasome) and β1i-β2-β5i (double intermediate proteasome). In this study, we use a tandem mass tag-quantification approach to study the production of six spliced human antigenic peptides by the four proteasome subtypes. Peptides fibroblast growth factor-5172-176/217-220, tyrosinase368-373/336-340, and gp10040-42/47-52 are better produced by the SP than the other proteasome subtypes. The peptides SP110296-301/286-289, gp100195-202/191or192, and gp10047-52/40-42 are better produced by the immunoproteasome and double intermediate proteasome. The current model of proteasome-catalyzed peptide splicing suggests that the production of a spliced peptide depends on the abundance of the peptide splicing partners. Surprisingly, we found that despite the fact that reciprocal peptides RTK_QLYPEW (gp10040-42/47-52) and QLYPEW_RTK (gp10047-52/40-42) are composed of identical splicing partners, their production varies differently according to the proteasome subtype. These differences were maintained after in vitro digestions involving identical amounts of the splicing fragments. Our results indicate that the amount of splicing partner is not the only factor driving peptide splicing and suggest that peptide splicing efficiency also relies on other factors, such as the affinity of the C-terminal splice reactant for the primed binding site of the catalytic subunit.
Collapse
Affiliation(s)
- Violette Ferrari
- Ludwig Institute for Cancer Research, Brussels, Belgium
- de Duve Institute, Université Catholique de Louvain, Brussels, Belgium
- Walloon Excellence in Lifesciences and Biotechnology, Brussels, Belgium; and
| | - Vincent Stroobant
- Ludwig Institute for Cancer Research, Brussels, Belgium
- de Duve Institute, Université Catholique de Louvain, Brussels, Belgium
- Walloon Excellence in Lifesciences and Biotechnology, Brussels, Belgium; and
| | - Joanna Abi Habib
- Ludwig Institute for Cancer Research, Brussels, Belgium
- de Duve Institute, Université Catholique de Louvain, Brussels, Belgium
- Walloon Excellence in Lifesciences and Biotechnology, Brussels, Belgium; and
| | - Stefan Naulaerts
- Ludwig Institute for Cancer Research, Brussels, Belgium
- de Duve Institute, Université Catholique de Louvain, Brussels, Belgium
- Walloon Excellence in Lifesciences and Biotechnology, Brussels, Belgium; and
| | - Benoit J Van den Eynde
- Ludwig Institute for Cancer Research, Brussels, Belgium;
- de Duve Institute, Université Catholique de Louvain, Brussels, Belgium
- Walloon Excellence in Lifesciences and Biotechnology, Brussels, Belgium; and
- Nuffield Department of Medicine, Ludwig Institute for Cancer Research, University of Oxford, Oxford, United Kingdom
| | - Nathalie Vigneron
- Ludwig Institute for Cancer Research, Brussels, Belgium;
- de Duve Institute, Université Catholique de Louvain, Brussels, Belgium
- Walloon Excellence in Lifesciences and Biotechnology, Brussels, Belgium; and
| |
Collapse
|
6
|
Global analysis of biosynthetic gene clusters reveals conserved and unique natural products in entomopathogenic nematode-symbiotic bacteria. Nat Chem 2022; 14:701-712. [PMID: 35469007 PMCID: PMC9177418 DOI: 10.1038/s41557-022-00923-2] [Citation(s) in RCA: 33] [Impact Index Per Article: 16.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/22/2021] [Accepted: 02/24/2022] [Indexed: 12/27/2022]
Abstract
Microorganisms contribute to the biology and physiology of eukaryotic hosts and affect other organisms through natural products. Xenorhabdus and Photorhabdus (XP) living in mutualistic symbiosis with entomopathogenic nematodes generate natural products to mediate bacteria–nematode–insect interactions. However, a lack of systematic analysis of the XP biosynthetic gene clusters (BGCs) has limited the understanding of how natural products affect interactions between the organisms. Here we combine pangenome and sequence similarity networks to analyse BGCs from 45 XP strains that cover all sequenced strains in our collection and represent almost all XP taxonomy. The identified 1,000 BGCs belong to 176 families. The most conserved families are denoted by 11 BGC classes. We homologously (over)express the ubiquitous and unique BGCs and identify compounds featuring unusual architectures. The bioactivity evaluation demonstrates that the prevalent compounds are eukaryotic proteasome inhibitors, virulence factors against insects, metallophores and insect immunosuppressants. These findings explain the functional basis of bacterial natural products in this tripartite relationship. ![]()
Entomopathogenic nematodes carrying Xenorhabdus and Photorhabdus bacteria prey on insect larvae in the soil. Now, a comprehensive analysis of the bacterial genome has revealed ubiquitous and unique families of biosynthetic gene clusters. Evaluation of the bioactivity of the natural products expressed by the most prevalent cluster families explains the functional basis of bacterial natural products involved in bacteria–nematode–insect interactions.
Collapse
|
7
|
Serrano-Aparicio N, Ferrer S, Świderek K. Covalent Inhibition of the Human 20S Proteasome with Homobelactosin C Inquired by QM/MM Studies. Pharmaceuticals (Basel) 2022; 15:ph15050531. [PMID: 35631358 PMCID: PMC9143130 DOI: 10.3390/ph15050531] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/31/2022] [Revised: 04/21/2022] [Accepted: 04/22/2022] [Indexed: 12/02/2022] Open
Abstract
20S proteasome is a main player in the protein degradation pathway in the cytosol, thus intervening in multiple pivotal cellular processes. Over the years the proteasome has emerged as a crucial target for the treatment of many diseases such as neurodegenerative diseases, cancer, autoimmune diseases, developmental disorders, cystic fibrosis, diabetes, cardiac diseases, atherosclerosis, and aging. In this work, the mechanism of proteasome covalent inhibition with bisbenzyl-protected homobelactosin C (hBelC) was explored using quantum mechanics/molecular mechanics (QM/MM) methods. Molecular dynamic simulations were used to describe key interactions established between the hBelC and its unique binding mode in the primed site of the β5 subunit. The free energy surfaces were computed to characterize the kinetics and thermodynamics of the inhibition process. This study revealed that although the final inhibition product for hBelC is formed according to the same molecular mechanism as one described for hSalA, the free energy profile of the reaction pathway differs significantly from the one previously reported for γ-lactam-β-lactone containing inhibitors in terms of the height of the activation barrier as well as the stabilization of the final product. Moreover, it was proved that high stabilization of the covalent adduct formed between β5-subunit and hBelC, together with the presence of aminocarbonyl side chain in the structure of the inhibitor which prevents the hydrolysis of the ester bond from taking place, determines its irreversible character.
Collapse
|
8
|
Functional Differences between Proteasome Subtypes. Cells 2022; 11:cells11030421. [PMID: 35159231 PMCID: PMC8834425 DOI: 10.3390/cells11030421] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2021] [Revised: 01/11/2022] [Accepted: 01/14/2022] [Indexed: 12/30/2022] Open
Abstract
Four proteasome subtypes are commonly present in mammalian tissues: standard proteasomes, which contain the standard catalytic subunits β1, β2 and β5; immunoproteasomes containing the immuno-subunits β1i, β2i and β5i; and two intermediate proteasomes, containing a mix of standard and immuno-subunits. Recent studies revealed the expression of two tissue-specific proteasome subtypes in cortical thymic epithelial cells and in testes: thymoproteasomes and spermatoproteasomes. In this review, we describe the mechanisms that enable the ATP- and ubiquitin-dependent as well as the ATP- and ubiquitin-independent degradation of proteins by the proteasome. We focus on understanding the role of the different proteasome subtypes in maintaining protein homeostasis in normal physiological conditions through the ATP- and ubiquitin-dependent degradation of proteins. Additionally, we discuss the role of each proteasome subtype in the ATP- and ubiquitin-independent degradation of disordered proteins. We also discuss the role of the proteasome in the generation of peptides presented by MHC class I molecules and the implication of having different proteasome subtypes for the peptide repertoire presented at the cell surface. Finally, we discuss the role of the immunoproteasome in immune cells and its modulation as a potential therapy for autoimmune diseases.
Collapse
|
9
|
Shimo S, Ushimaru R, Engelbrecht A, Harada M, Miyamoto K, Kulik A, Uchiyama M, Kaysser L, Abe I. Stereodivergent Nitrocyclopropane Formation during Biosynthesis of Belactosins and Hormaomycins. J Am Chem Soc 2021; 143:18413-18418. [PMID: 34710328 DOI: 10.1021/jacs.1c10201] [Citation(s) in RCA: 26] [Impact Index Per Article: 8.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
Belactosins and hormaomycins are peptide natural products containing 3-(2-aminocyclopropyl)alanine and 3-(2-nitrocyclopropyl)alanine residues, respectively, with opposite stereoconfigurations of the cyclopropane ring. Herein we demonstrate that the heme oxygenase-like enzymes BelK and HrmI catalyze the N-oxygenation of l-lysine to generate 6-nitronorleucine. The nonheme iron enzymes BelL and HrmJ then cyclize the nitroalkane moiety to the nitrocyclopropane ring with the desired stereochemistry found in the corresponding natural products. We also show that both cyclopropanases remove the 4-proS-H of 6-nitronorleucine during the cyclization, establishing the inversion and retention of the configuration at C4 during the BelL and HrmJ reactions, respectively. This study reveals the unique strategy for stereocontrolled cyclopropane synthesis in nature.
Collapse
Affiliation(s)
- Shotaro Shimo
- Graduate School of Pharmaceutical Sciences, The University of Tokyo, Bunkyo-ku, Tokyo 113-0033, Japan
| | - Richiro Ushimaru
- Graduate School of Pharmaceutical Sciences, The University of Tokyo, Bunkyo-ku, Tokyo 113-0033, Japan.,Collaborative Research Institute for Innovative Microbiology, The University of Tokyo, Bunkyo-ku, Tokyo 113-0033, Japan.,ACT-X, Japan Science and Technology Agency (JST), Honcho, Kawaguchi, Saitama 332-0012, Japan
| | - Alicia Engelbrecht
- Pharmaceutical Institute, Department of Pharmaceutical Biology, University of Tübingen, Auf der Morgenstelle 8, 72076 Tübingen, Germany
| | - Mei Harada
- Graduate School of Pharmaceutical Sciences, The University of Tokyo, Bunkyo-ku, Tokyo 113-0033, Japan
| | - Kazunori Miyamoto
- Graduate School of Pharmaceutical Sciences, The University of Tokyo, Bunkyo-ku, Tokyo 113-0033, Japan
| | - Andreas Kulik
- Interfaculty Institute of Microbiology and Infection Medicine (IMIT), University of Tübingen, 72076 Tübingen, Germany
| | - Masanobu Uchiyama
- Graduate School of Pharmaceutical Sciences, The University of Tokyo, Bunkyo-ku, Tokyo 113-0033, Japan.,Research Initiative for Supra-Materials (RISM), Shinshu University, Ueda, 386-8567, Japan
| | - Leonard Kaysser
- Institute for Drug Discovery, Department of Pharmaceutical Biology, University of Leipzig, Eilenburger Str. 14, 04317 Leipzig, Germany
| | - Ikuro Abe
- Graduate School of Pharmaceutical Sciences, The University of Tokyo, Bunkyo-ku, Tokyo 113-0033, Japan.,Collaborative Research Institute for Innovative Microbiology, The University of Tokyo, Bunkyo-ku, Tokyo 113-0033, Japan
| |
Collapse
|
10
|
Wang J, Liang B, Chen Y, Fuk-Woo Chan J, Yuan S, Ye H, Nie L, Zhou J, Wu Y, Wu M, Huang LS, An J, Warshel A, Yuen KY, Ciechanover A, Huang Z, Xu Y. A new class of α-ketoamide derivatives with potent anticancer and anti-SARS-CoV-2 activities. Eur J Med Chem 2021; 215:113267. [PMID: 33639344 PMCID: PMC7873610 DOI: 10.1016/j.ejmech.2021.113267] [Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/28/2020] [Revised: 01/30/2021] [Accepted: 01/30/2021] [Indexed: 12/27/2022]
Abstract
Inhibitors of the proteasome have been extensively studied for their applications in the treatment of human diseases such as hematologic malignancies, autoimmune disorders, and viral infections. Many of the proteasome inhibitors reported in the literature target the non-primed site of proteasome’s substrate binding pocket. In this study, we designed, synthesized and characterized a series of novel α-keto phenylamide derivatives aimed at both the primed and non-primed sites of the proteasome. In these derivatives, different substituted phenyl groups at the head group targeting the primed site were incorporated in order to investigate their structure-activity relationship and optimize the potency of α-keto phenylamides. In addition, the biological effects of modifications at the cap moiety, P1, P2 and P3 side chain positions were explored. Many derivatives displayed highly potent biological activities in proteasome inhibition and anticancer activity against a panel of six cancer cell lines, which were further rationalized by molecular modeling analyses. Furthermore, a representative α-ketoamide derivative was tested and found to be active in inhibiting the cellular infection of SARS-CoV-2 which causes the COVID-19 pandemic. These results demonstrate that this new class of α-ketoamide derivatives are potent anticancer agents and provide experimental evidence of the anti-SARS-CoV-2 effect by one of them, thus suggesting a possible new lead to develop antiviral therapeutics for COVID-19.
Collapse
Affiliation(s)
- Juan Wang
- School of Life Sciences, Tsinghua University, Beijing, 100084, China
| | - Boqiang Liang
- Nobel Institute of Biomedicine, Zhuhai, 519000, China
| | - Yiling Chen
- Nobel Institute of Biomedicine, Zhuhai, 519000, China
| | - Jasper Fuk-Woo Chan
- State Key Laboratory of Emerging Infectious Diseases, Carol Yu Centre for Infection, Department of Microbiology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong, China
| | - Shuofeng Yuan
- State Key Laboratory of Emerging Infectious Diseases, Carol Yu Centre for Infection, Department of Microbiology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong, China
| | - Hui Ye
- Nobel Institute of Biomedicine, Zhuhai, 519000, China
| | - Linlin Nie
- Nobel Institute of Biomedicine, Zhuhai, 519000, China
| | - Jiao Zhou
- Nobel Institute of Biomedicine, Zhuhai, 519000, China; Ciechanover Institute of Precision and Regenerative Medicine, School of Life and Health Sciences, Chinese University of Hong Kong, Shenzhen, 518172, China
| | - Yi Wu
- Nobel Institute of Biomedicine, Zhuhai, 519000, China
| | - Meixian Wu
- Department of Medicine, Division of Infectious Diseases and Global Public Health, School of Medicine, University of California San Diego, La Jolla, CA, 92037, USA
| | - Lina S Huang
- Department of Medicine, Division of Infectious Diseases and Global Public Health, School of Medicine, University of California San Diego, La Jolla, CA, 92037, USA
| | - Jing An
- Department of Medicine, Division of Infectious Diseases and Global Public Health, School of Medicine, University of California San Diego, La Jolla, CA, 92037, USA
| | - Arieh Warshel
- Department of Chemistry, University of Southern California, Los Angeles, CA, 90089, USA
| | - Kwok-Yung Yuen
- State Key Laboratory of Emerging Infectious Diseases, Carol Yu Centre for Infection, Department of Microbiology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong, China
| | - Aaron Ciechanover
- Nobel Institute of Biomedicine, Zhuhai, 519000, China; Technion-Israel Institute of Technology, Haifa, 3109601, Israel
| | - Ziwei Huang
- School of Life Sciences, Tsinghua University, Beijing, 100084, China; Department of Medicine, Division of Infectious Diseases and Global Public Health, School of Medicine, University of California San Diego, La Jolla, CA, 92037, USA; Ciechanover Institute of Precision and Regenerative Medicine, School of Life and Health Sciences, Chinese University of Hong Kong, Shenzhen, 518172, China.
| | - Yan Xu
- Nobel Institute of Biomedicine, Zhuhai, 519000, China; Ciechanover Institute of Precision and Regenerative Medicine, School of Life and Health Sciences, Chinese University of Hong Kong, Shenzhen, 518172, China.
| |
Collapse
|
11
|
Hubbell GE, Tepe JJ. Natural product scaffolds as inspiration for the design and synthesis of 20S human proteasome inhibitors. RSC Chem Biol 2020; 1:305-332. [PMID: 33791679 PMCID: PMC8009326 DOI: 10.1039/d0cb00111b] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/29/2020] [Accepted: 09/01/2020] [Indexed: 12/13/2022] Open
Abstract
The 20S proteasome is a valuable target for the treatment of a number of diseases including cancer, neurodegenerative disease, and parasitic infection. In an effort to discover novel inhibitors of the 20S proteasome, many reseaarchers have looked to natural products as potential leads for drug discovery. The following review discusses the efforts made in the field to isolate and identify natural products as inhibitors of the proteasome. In addition, we describe some of the modifications made to natural products in order to discover more potent and selective inhibitors for potential disease treatment.
Collapse
Affiliation(s)
- Grace E. Hubbell
- Department of Chemistry, Michigan State UniversityEast LansingMI 48823USA
| | - Jetze J. Tepe
- Department of Chemistry, Michigan State UniversityEast LansingMI 48823USA
| |
Collapse
|
12
|
Kaysser L. Built to bind: biosynthetic strategies for the formation of small-molecule protease inhibitors. Nat Prod Rep 2019; 36:1654-1686. [DOI: 10.1039/c8np00095f] [Citation(s) in RCA: 16] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
Abstract
The discovery and characterization of natural product protease inhibitors has inspired the development of numerous pharmaceutical agents.
Collapse
Affiliation(s)
- Leonard Kaysser
- Department of Pharmaceutical Biology
- University of Tübingen
- 72076 Tübingen
- Germany
- German Centre for Infection Research (DZIF)
| |
Collapse
|
13
|
Design, synthesis, and evaluation of cystargolide-based β-lactones as potent proteasome inhibitors. Eur J Med Chem 2018; 157:962-977. [PMID: 30165344 DOI: 10.1016/j.ejmech.2018.08.052] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/25/2018] [Revised: 08/15/2018] [Accepted: 08/18/2018] [Indexed: 11/20/2022]
Abstract
The peptidic β-lactone proteasome inhibitors (PIs) cystargolides A and B were used to conduct structure-activity relationship (SAR) studies in order to assess their anticancer potential. A total of 24 different analogs were designed, synthesized and evaluated for proteasome inhibition, for cytotoxicity towards several cancer cell lines, and for their ability to enter intact cells. X-ray crystallographic analysis and subunit selectivity was used to determine the specific subunit binding associated with the structural modification of the β-lactone (P1), peptidic core, (Px and Py), and end-cap (Pz) of our scaffold. The cystargolide derivative 5k, structurally unique at both Py and P1, exhibited the most promising inhibitory activity for the β5 subunit of human proteasomes (IC50 = 3.1 nM) and significant cytotoxicity towards MCF-7 (IC50 = 416 nM), MDA-MB-231 (IC50 = 74 nM) and RPMI 8226 (IC50 = 41 nM) cancer cell lines. Cellular infiltration assays revealed that minor structural modifications have significant effects on the ability of our PIs to inhibit intracellular proteasomes, and we identified 5k as a promising candidate for continued therapeutic studies. Our novel drug lead 5k is a more potent proteasome inhibitor than carfilzomib with mid-to-low nanomolar IC50 measurements and it is cytotoxic against multiple cancer cell lines at levels approaching those of carfilzomib.
Collapse
|
14
|
Simaan M, Marek I. Asymmetric Catalytic Preparation of Polysubstituted Cyclopropanol and Cyclopropylamine Derivatives. Angew Chem Int Ed Engl 2018; 57:1543-1546. [PMID: 29320599 DOI: 10.1002/anie.201710707] [Citation(s) in RCA: 59] [Impact Index Per Article: 9.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/17/2017] [Revised: 11/23/2017] [Indexed: 01/08/2023]
Abstract
The catalytic asymmetric carbometalation of cyclopropenes followed by either an electrophilic oxidation or amination reaction provides a unique approach to the formation of diastereomerically pure and enantiomerically enriched cyclopropanol and cyclopropylamine derivatives, respectively.
Collapse
Affiliation(s)
- Marwan Simaan
- The Mallat Family Laboratory of Organic Chemistry, Schulich Faculty of Chemistry, Technion-Israel Institute of Technology, Haifa, 3200009, Israel
| | - Ilan Marek
- The Mallat Family Laboratory of Organic Chemistry, Schulich Faculty of Chemistry, Technion-Israel Institute of Technology, Haifa, 3200009, Israel
| |
Collapse
|
15
|
Simaan M, Marek I. Asymmetric Catalytic Preparation of Polysubstituted Cyclopropanol and Cyclopropylamine Derivatives. Angew Chem Int Ed Engl 2018. [DOI: 10.1002/ange.201710707] [Citation(s) in RCA: 29] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/09/2023]
Affiliation(s)
- Marwan Simaan
- The Mallat Family Laboratory of Organic Chemistry; Schulich Faculty of Chemistry; Technion-Israel Institute of Technology; Haifa 3200009 Israel
| | - Ilan Marek
- The Mallat Family Laboratory of Organic Chemistry; Schulich Faculty of Chemistry; Technion-Israel Institute of Technology; Haifa 3200009 Israel
| |
Collapse
|
16
|
Hovhannisyan AA, Pham TH, Bouvier D, Tan X, Touhar S, Mkryan GG, Dallakyan AM, El Amri C, Melikyan GS, Reboud-Ravaux M, Bouvier-Durand M. Phenoxypropanolamine derivatives as selective inhibitors of the 20S proteasome β1 and β5 subunits. Bioorg Med Chem Lett 2017; 27:5172-5178. [PMID: 29113763 DOI: 10.1016/j.bmcl.2017.10.055] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/13/2017] [Revised: 10/20/2017] [Accepted: 10/22/2017] [Indexed: 10/18/2022]
Abstract
New series of thiophene-containing phenoxypropanolamines were synthesized and evaluated for their potency to inhibit the three proteolytic activities of the mammalian 20S proteasome. Noticeable inhibition of both ChT-L and PA activities was obtained with three compounds: one with unsubstituted phenoxypropanolamine group (7) and the two others with a p-Cl-substituted group (4 and 9). For three other compounds (3, 8 and 10), ChT-L activity alone was significantly inhibited. In silico docking performed on the β5 and β1 subunits bearing the respective ChT-L and PA catalytic sites showed features common to poses associated with active compounds. These features may constitute a selectivity criterion for structure-guided inhibitor design.
Collapse
Affiliation(s)
- Anna A Hovhannisyan
- Department of Organic Chemistry, Yerevan State University, 1 Alex Manoogian Str., 0025 Yerevan, Armenia
| | - The Hien Pham
- Sorbonne Universités, UPMC Univ Paris 06, IBPS, CNRS UMR 8256, Biological Adaptation and Ageing (B2A), Integrated Cellular Ageing and Inflammation, 7 Quai St Bernard, 75005 Paris, France
| | - Dominique Bouvier
- Sorbonne Universités, UPMC Univ Paris 06, Atelier de BioInformatique, ISYEB, UMR 7205 CNRS MNHN UPMC EPHE, Museum national d'Histoire naturelle, CP 50, 45 rue Buffon, 75005 Paris Cedex 05, France
| | - Xiao Tan
- Sorbonne Universités, UPMC Univ Paris 06, IBPS, CNRS UMR 8256, Biological Adaptation and Ageing (B2A), Integrated Cellular Ageing and Inflammation, 7 Quai St Bernard, 75005 Paris, France
| | - SiAmmar Touhar
- Sorbonne Universités, UPMC Univ Paris 06, IBPS, CNRS UMR 8256, Biological Adaptation and Ageing (B2A), Integrated Cellular Ageing and Inflammation, 7 Quai St Bernard, 75005 Paris, France
| | - Gevorg G Mkryan
- The Scientific Technological Centre of Organic and Pharmaceutical Chemistry HAS A.L.Mnjoyan Institute of Fine Organic Chemistry, 26 Azatutyan Str., Yerevan 0014, Armenia
| | - Ashot M Dallakyan
- The Scientific Technological Centre of Organic and Pharmaceutical Chemistry HAS A.L.Mnjoyan Institute of Fine Organic Chemistry, 26 Azatutyan Str., Yerevan 0014, Armenia
| | - Chahrazade El Amri
- Sorbonne Universités, UPMC Univ Paris 06, IBPS, CNRS UMR 8256, Biological Adaptation and Ageing (B2A), Integrated Cellular Ageing and Inflammation, 7 Quai St Bernard, 75005 Paris, France
| | - Gagik S Melikyan
- Department of Organic Chemistry, Yerevan State University, 1 Alex Manoogian Str., 0025 Yerevan, Armenia
| | - Michèle Reboud-Ravaux
- Sorbonne Universités, UPMC Univ Paris 06, IBPS, CNRS UMR 8256, Biological Adaptation and Ageing (B2A), Integrated Cellular Ageing and Inflammation, 7 Quai St Bernard, 75005 Paris, France
| | - Michelle Bouvier-Durand
- Sorbonne Universités, UPMC Univ Paris 06, IBPS, CNRS UMR 8256, Biological Adaptation and Ageing (B2A), Integrated Cellular Ageing and Inflammation, 7 Quai St Bernard, 75005 Paris, France.
| |
Collapse
|
17
|
Marastoni M, Trapella C, Scotti A, Fantinati A, Ferretti V, Marzola E, Eleonora G, Gavioli R, Preti D. Naphthoquinone amino acid derivatives, synthesis and biological activity as proteasome inhibitors. J Enzyme Inhib Med Chem 2017; 32:865-877. [PMID: 28657369 PMCID: PMC6445160 DOI: 10.1080/14756366.2017.1334649] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022] Open
Abstract
The ubiquitin-proteasome system has been largely investigated for its key role in protein degradation mechanisms that regulate both apoptosis and cell division. Because of their antitumour activity, different classes of proteasome inhibitors have been identified to date. Some of these compounds are currently employed in the clinical treatment of several types of cancer among which multiple myeloma. Here, we describe the design, chemistry, biological activity and modelling studies of a large series of amino acid derivatives linked to a naphthoquinone pharmacophoric group through variable spacers. Some analogues showed interesting inhibitory potency for the β1 and β5 subunits of the proteasome with IC50 values in the sub-µm range.
Collapse
Affiliation(s)
- Mauro Marastoni
- a Department of Chemical and Pharmaceutical Sciences , University of Ferrara , Ferrara , Italy
| | - Claudio Trapella
- a Department of Chemical and Pharmaceutical Sciences , University of Ferrara , Ferrara , Italy
| | - Alessandra Scotti
- a Department of Chemical and Pharmaceutical Sciences , University of Ferrara , Ferrara , Italy
| | - Anna Fantinati
- a Department of Chemical and Pharmaceutical Sciences , University of Ferrara , Ferrara , Italy
| | - Valeria Ferretti
- a Department of Chemical and Pharmaceutical Sciences , University of Ferrara , Ferrara , Italy
| | - Erika Marzola
- a Department of Chemical and Pharmaceutical Sciences , University of Ferrara , Ferrara , Italy
| | - Gallerani Eleonora
- b Department of Life Sciences and Biotechnology , University of Ferrara , Ferrara , Italy
| | - Riccardo Gavioli
- b Department of Life Sciences and Biotechnology , University of Ferrara , Ferrara , Italy
| | - Delia Preti
- a Department of Chemical and Pharmaceutical Sciences , University of Ferrara , Ferrara , Italy
| |
Collapse
|
18
|
Zhu M, Harshbarger WD, Robles O, Krysiak J, Hull KG, Cho SW, Richardson RD, Yang Y, Garcia A, Spiegelman L, Ramirez B, Wilson CT, Yau JA, Moore JT, Walker CB, Sacchettini JC, Liu WR, Sieber SA, Smith JW, Romo D. A strategy for dual inhibition of the proteasome and fatty acid synthase with belactosin C-orlistat hybrids. Bioorg Med Chem 2017; 25:2901-2916. [PMID: 28236510 PMCID: PMC5522751 DOI: 10.1016/j.bmc.2017.01.020] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/23/2016] [Accepted: 01/13/2017] [Indexed: 11/21/2022]
Abstract
The proteasome, a validated cellular target for cancer, is central for maintaining cellular homeostasis, while fatty acid synthase (FAS), a novel target for numerous cancers, is responsible for palmitic acid biosynthesis. Perturbation of either enzymatic machine results in decreased proliferation and ultimately cellular apoptosis. Based on structural similarities, we hypothesized that hybrid molecules of belactosin C, a known proteasome inhibitor, and orlistat, a known inhibitor of the thioesterase domain of FAS, could inhibit both enzymes. Herein, we describe proof-of-principle studies leading to the design, synthesis and enzymatic activity of several novel, β-lactone-based, dual inhibitors of these two enzymes. Validation of dual enzyme targeting through activity-based proteome profiling with an alkyne probe modeled after the most potent inhibitor, and preliminary serum stability studies of selected derivatives are also described. These results provide proof of concept for dual targeting of the proteasome and fatty acid synthase-thioesterase (FAS-TE) enabling a new approach for the development of drug-candidates with potential to overcome resistance.
Collapse
Affiliation(s)
- Mingzhao Zhu
- Department of Chemistry & Biochemistry and CPRIT Synthesis and Drug-Lead Discovery Laboratory, Baylor University, Waco, TX 76706, USA
| | - Wayne D Harshbarger
- Department of Biochemistry & Biophysics, Texas A&M University, College Station, TX 77840, USA
| | - Omar Robles
- Department of Chemistry, Texas A&M University, College Station, TX 77842, USA
| | - Joanna Krysiak
- Department of Chemistry, Technische Universität München, Lichtenbergstr. 4, 85747 Garching, Germany
| | - Kenneth G Hull
- Department of Chemistry & Biochemistry and CPRIT Synthesis and Drug-Lead Discovery Laboratory, Baylor University, Waco, TX 76706, USA
| | - Sung Wook Cho
- Department of Chemistry, Texas A&M University, College Station, TX 77842, USA
| | | | - Yanyan Yang
- Department of Chemistry, Texas A&M University, College Station, TX 77842, USA
| | - Andres Garcia
- Department of Chemistry, Texas A&M University, College Station, TX 77842, USA
| | - Lindsey Spiegelman
- Department of Chemistry, Texas A&M University, College Station, TX 77842, USA
| | - Bianca Ramirez
- Department of Chemistry, Texas A&M University, College Station, TX 77842, USA
| | | | - Ju Anne Yau
- Department of Chemistry, Texas A&M University, College Station, TX 77842, USA
| | - James T Moore
- Department of Chemistry, Texas A&M University, College Station, TX 77842, USA
| | - Caitlen B Walker
- Department of Chemistry, Texas A&M University, College Station, TX 77842, USA
| | - James C Sacchettini
- Department of Biochemistry & Biophysics, Texas A&M University, College Station, TX 77840, USA
| | - Wenshe R Liu
- Department of Chemistry, Texas A&M University, College Station, TX 77842, USA
| | - Stephan A Sieber
- Department of Chemistry, Technische Universität München, Lichtenbergstr. 4, 85747 Garching, Germany
| | - Jeffrey W Smith
- Sanford Burnham Medical Research Institute, La Jolla, CA, USA
| | - Daniel Romo
- Department of Chemistry & Biochemistry and CPRIT Synthesis and Drug-Lead Discovery Laboratory, Baylor University, Waco, TX 76706, USA.
| |
Collapse
|
19
|
Wolf F, Bauer JS, Bendel TM, Kulik A, Kalinowski J, Gross H, Kaysser L. Die Biosynthese der β-Lacton-haltigen Proteasominhibitoren Belactosin und Cystargolid. Angew Chem Int Ed Engl 2017. [DOI: 10.1002/ange.201612076] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/11/2023]
Affiliation(s)
- Felix Wolf
- Abteilung Pharmazeutische Biologie; Pharmazeutisches Institut; Universität Tübingen; 72076 Tübingen Deutschland
- Deutsches Zentrum für Infektionsforschung (DZIF); Standort Tübingen; 72076 Tübingen Deutschland
| | - Judith S. Bauer
- Abteilung Pharmazeutische Biologie; Pharmazeutisches Institut; Universität Tübingen; 72076 Tübingen Deutschland
- Deutsches Zentrum für Infektionsforschung (DZIF); Standort Tübingen; 72076 Tübingen Deutschland
| | - Theresa M. Bendel
- Abteilung Pharmazeutische Biologie; Pharmazeutisches Institut; Universität Tübingen; 72076 Tübingen Deutschland
- Deutsches Zentrum für Infektionsforschung (DZIF); Standort Tübingen; 72076 Tübingen Deutschland
| | - Andreas Kulik
- Interfaculty Institute for Microbiology and Infection Medicine, Tübingen (IMIT); Mikrobiologie/Biotechnologie; Universität Tübingen; 72076 Tübingen Deutschland
| | - Jörn Kalinowski
- Center for Biotechnology (CeBiTec); Universität Bielefeld; 33615 Bielefeld Deutschland
| | - Harald Gross
- Abteilung Pharmazeutische Biologie; Pharmazeutisches Institut; Universität Tübingen; 72076 Tübingen Deutschland
- Deutsches Zentrum für Infektionsforschung (DZIF); Standort Tübingen; 72076 Tübingen Deutschland
| | - Leonard Kaysser
- Abteilung Pharmazeutische Biologie; Pharmazeutisches Institut; Universität Tübingen; 72076 Tübingen Deutschland
- Deutsches Zentrum für Infektionsforschung (DZIF); Standort Tübingen; 72076 Tübingen Deutschland
| |
Collapse
|
20
|
Wolf F, Bauer JS, Bendel TM, Kulik A, Kalinowski J, Gross H, Kaysser L. Biosynthesis of the β-Lactone Proteasome Inhibitors Belactosin and Cystargolide. Angew Chem Int Ed Engl 2017; 56:6665-6668. [PMID: 28452105 DOI: 10.1002/anie.201612076] [Citation(s) in RCA: 26] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/12/2016] [Indexed: 01/06/2023]
Abstract
Belactosins and cystargolides are natural product proteasome inhibitors from Actinobacteria. Both feature dipeptidic backbones and a unique β-lactone building block. Herein, we present a detailed investigation of their biosynthesis. Identification and analysis of the corresponding gene clusters indicated that both compounds are assembled by rare single-enzyme amino acid ligases. Feeding experiments with isotope-labeled precursors and in vitro biochemistry showed that the formation of the β-lactone warhead is unprecedented and reminiscent of leucine biosynthesis, and that it involves the action of isopropylmalate synthase homologues.
Collapse
Affiliation(s)
- Felix Wolf
- Department of Pharmaceutical Biology, Pharmaceutical Institute, University of Tuebingen, 72076, Tuebingen, Germany.,German Centre for Infection Research (DZIF), partner site Tuebingen, 72076, Tuebingen, Germany
| | - Judith S Bauer
- Department of Pharmaceutical Biology, Pharmaceutical Institute, University of Tuebingen, 72076, Tuebingen, Germany.,German Centre for Infection Research (DZIF), partner site Tuebingen, 72076, Tuebingen, Germany
| | - Theresa M Bendel
- Department of Pharmaceutical Biology, Pharmaceutical Institute, University of Tuebingen, 72076, Tuebingen, Germany.,German Centre for Infection Research (DZIF), partner site Tuebingen, 72076, Tuebingen, Germany
| | - Andreas Kulik
- Interfaculty Institute for Microbiology and Infection Medicine Tuebingen (IMIT), Microbiology/Biotechnology, University of Tuebingen, 72076, Tuebingen, Germany
| | - Jörn Kalinowski
- Center for Biotechnology (CeBiTec), University of Bielefeld, 33615, Bielefeld, Germany
| | - Harald Gross
- Department of Pharmaceutical Biology, Pharmaceutical Institute, University of Tuebingen, 72076, Tuebingen, Germany.,German Centre for Infection Research (DZIF), partner site Tuebingen, 72076, Tuebingen, Germany
| | - Leonard Kaysser
- Department of Pharmaceutical Biology, Pharmaceutical Institute, University of Tuebingen, 72076, Tuebingen, Germany.,German Centre for Infection Research (DZIF), partner site Tuebingen, 72076, Tuebingen, Germany
| |
Collapse
|
21
|
Synthesis and biological evaluation of α-methyl-chalcone for anti-cervical cancer activity. Med Chem Res 2017. [DOI: 10.1007/s00044-017-1891-0] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
22
|
Qin JM, Huang RZ, Yao GY, Liao ZX, Pan YM, Wang HS. Terminal functionalized thiourea-containing dipeptides as multidrug-resistance reversers that target 20S proteasome and cell proliferation. Eur J Med Chem 2017; 126:259-269. [DOI: 10.1016/j.ejmech.2016.11.024] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/13/2016] [Revised: 11/07/2016] [Accepted: 11/10/2016] [Indexed: 12/30/2022]
|
23
|
A unified mechanism for proteolysis and autocatalytic activation in the 20S proteasome. Nat Commun 2016; 7:10900. [PMID: 26964885 PMCID: PMC4792962 DOI: 10.1038/ncomms10900] [Citation(s) in RCA: 73] [Impact Index Per Article: 9.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/10/2015] [Accepted: 01/31/2016] [Indexed: 11/28/2022] Open
Abstract
Biogenesis of the 20S proteasome is tightly regulated. The N-terminal propeptides protecting the active-site threonines are autocatalytically released only on completion of assembly. However, the trigger for the self-activation and the reason for the strict conservation of threonine as the active site nucleophile remain enigmatic. Here we use mutagenesis, X-ray crystallography and biochemical assays to suggest that Lys33 initiates nucleophilic attack of the propeptide by deprotonating the Thr1 hydroxyl group and that both residues together with Asp17 are part of a catalytic triad. Substitution of Thr1 by Cys disrupts the interaction with Lys33 and inactivates the proteasome. Although a Thr1Ser mutant is active, it is less efficient compared with wild type because of the unfavourable orientation of Ser1 towards incoming substrates. This work provides insights into the basic mechanism of proteolysis and propeptide autolysis, as well as the evolutionary pressures that drove the proteasome to become a threonine protease. The proteasome, an essential molecular machine, is a threonine protease, but the evolution and the components of its proteolytic centre are unclear. Here, the authors use structural biology and biochemistry to investigate the role of proteasome active site residues on maturation and activity.
Collapse
|
24
|
Śledź P, Baumeister W. Structure-Driven Developments of 26S Proteasome Inhibitors. Annu Rev Pharmacol Toxicol 2016; 56:191-209. [DOI: 10.1146/annurev-pharmtox-010814-124727] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- Paweł Śledź
- Department of Molecular Structural Biology, Max Planck Institute of Biochemistry, 82152 Martinsried, Germany;
| | - Wolfgang Baumeister
- Department of Molecular Structural Biology, Max Planck Institute of Biochemistry, 82152 Martinsried, Germany;
| |
Collapse
|
25
|
Groll M, Korotkov VS, Huber EM, de Meijere A, Ludwig A. Ein minimales β-Lacton-Gerüst für selektive β5c- oder β5i-Proteasominhibitoren. Angew Chem Int Ed Engl 2015. [DOI: 10.1002/ange.201502931] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
|
26
|
Groll M, Korotkov VS, Huber EM, de Meijere A, Ludwig A. A Minimal β-Lactone Fragment for Selective β5c or β5i Proteasome Inhibitors. Angew Chem Int Ed Engl 2015; 54:7810-4. [PMID: 25973989 DOI: 10.1002/anie.201502931] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/30/2015] [Indexed: 11/09/2022]
Abstract
Broad-spectrum proteasome inhibitors are applied as anticancer drugs, whereas selective blockage of the immunoproteasome represents a promising therapeutic rationale for autoimmune diseases. We here aimed at identifying minimal structural elements that confer β5c or β5i selectivity on proteasome inhibitors. Based on the natural product belactosin C, we synthesized two β-lactones featuring a dimethoxybenzyl moiety and either a methylpropyl (pseudo-isoleucin) or an isopropyl (pseudo-valine) P1 side chain. Although the two compounds differ only by one methyl group, the isoleucine analogue is six times more potent for β5i (IC50=14 nM) than the valine counterpart. Cell culture experiments demonstrate the cell-permeability of the compounds and X-ray crystallography data highlight them as minimal fragments that occupy primed and non-primed pockets of the active sites of the proteasome. Together, these results qualify β-lactones as a promising lead-structure motif for potent nonpeptidic proteasome inhibitors with diverse pharmaceutical applications.
Collapse
Affiliation(s)
- Michael Groll
- Center for Integrated Protein Science at the Department Chemie, Technische Universität München, Lichtenbergstrasse 4, 85748 Garching (Germany).
| | - Vadim S Korotkov
- Center for Integrated Protein Science at the Department Chemie, Technische Universität München, Lichtenbergstrasse 4, 85748 Garching (Germany)
| | - Eva M Huber
- Center for Integrated Protein Science at the Department Chemie, Technische Universität München, Lichtenbergstrasse 4, 85748 Garching (Germany)
| | - Armin de Meijere
- Institut für Organische und Biomolekulare Chemie der Georg-August-Universität Göttingen, Tammannstrasse 2, 37077 Göttingen (Germany)
| | - Antje Ludwig
- Charité Universitätsmedizin Berlin CCM, Medizinische Klinik für Kardiologie und Angiologie, Charitéplatz 1, 10117 Berlin (Germany).
| |
Collapse
|
27
|
Belogurov A, Kuzina E, Kudriaeva A, Kononikhin A, Kovalchuk S, Surina Y, Smirnov I, Lomakin Y, Bacheva A, Stepanov A, Karpova Y, Lyupina Y, Kharybin O, Melamed D, Ponomarenko N, Sharova N, Nikolaev E, Gabibov A. Ubiquitin-independent proteosomal degradation of myelin basic protein contributes to development of neurodegenerative autoimmunity. FASEB J 2015; 29:1901-13. [PMID: 25634956 PMCID: PMC4415016 DOI: 10.1096/fj.14-259333] [Citation(s) in RCA: 33] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/27/2014] [Accepted: 12/22/2014] [Indexed: 11/18/2022]
Abstract
Recent findings indicate that the ubiquitin–proteasome system is involved in the pathogenesis of cancer as well as autoimmune and several neurodegenerative diseases, and is thus a target for novel therapeutics. One disease that is related to aberrant protein degradation is multiple sclerosis, an autoimmune disorder involving the processing and presentation of myelin autoantigens that leads to the destruction of axons. Here, we show that brain-derived proteasomes from SJL mice with experimental autoimmune encephalomyelitis (EAE) in an ubiquitin-independent manner generate significantly increased amounts of myelin basic protein peptides that induces cytotoxic lymphocytes to target mature oligodendrocytes ex vivo. Ten times enhanced release of immunogenic peptides by cerebral proteasomes from EAE-SJL mice is caused by a dramatic shift in the balance between constitutive and β1ihigh immunoproteasomes in the CNS of SJL mice with EAE. We found that during EAE, β1i is increased in resident CNS cells, whereas β5i is imported by infiltrating lymphocytes through the blood–brain barrier. Peptidyl epoxyketone specifically inhibits brain-derived β1ihigh immunoproteasomes in vitro (kobs/[I] = 240 M−1s−1), and at a dose of 0.5 mg/kg, it ameliorates ongoing EAE in vivo. Therefore, our findings provide novel insights into myelin metabolism in pathophysiologic conditions and reveal that the β1i subunit of the immunoproteasome is a potential target to treat autoimmune neurologic diseases.—Belogurov Jr., A., Kuzina, E., Kudriaeva, A., Kononikhin, A., Kovalchuk, S., Surina, Y., Smirnov, I., Lomakin, Y., Bacheva, A., Stepanov, A., Karpova, Y., Lyupina, Y., Kharybin, O., Melamed, D., Ponomarenko, N., Sharova, N., Nikolaev, E., Gabibov, A. Ubiquitin-independent proteosomal degradation of myelin basic protein contributes to development of neurodegenerative autoimmunity.
Collapse
Affiliation(s)
- Alexey Belogurov
- *Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, Russia; Kazan Federal University, Kazan, Republic of Tatarstan, Russia; Institute of Gene Biology, Russian Acedemy of Sciences, Moscow, Russia; Chemistry Department of Moscow State University, Moscow, Russia; Moscow Institute of Physics and Technology, Dolgoprudnyi, Russia; Institute for Energy Problems of Chemical Physics, Russian Academy of Sciences, Moscow, Russia; Research Institute of Physico-Chemical Medicine, Moscow, Russia; **Institute of Developmental Biology, Russian Academy of Sciences, Moscow, Russia; Institute of Biomedical Chemistry, Russian Academy of Medical Sciences, Moscow, Russia; and Assaf Harofeh Medical Center, Zerifin, Israel
| | - Ekaterina Kuzina
- *Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, Russia; Kazan Federal University, Kazan, Republic of Tatarstan, Russia; Institute of Gene Biology, Russian Acedemy of Sciences, Moscow, Russia; Chemistry Department of Moscow State University, Moscow, Russia; Moscow Institute of Physics and Technology, Dolgoprudnyi, Russia; Institute for Energy Problems of Chemical Physics, Russian Academy of Sciences, Moscow, Russia; Research Institute of Physico-Chemical Medicine, Moscow, Russia; **Institute of Developmental Biology, Russian Academy of Sciences, Moscow, Russia; Institute of Biomedical Chemistry, Russian Academy of Medical Sciences, Moscow, Russia; and Assaf Harofeh Medical Center, Zerifin, Israel
| | - Anna Kudriaeva
- *Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, Russia; Kazan Federal University, Kazan, Republic of Tatarstan, Russia; Institute of Gene Biology, Russian Acedemy of Sciences, Moscow, Russia; Chemistry Department of Moscow State University, Moscow, Russia; Moscow Institute of Physics and Technology, Dolgoprudnyi, Russia; Institute for Energy Problems of Chemical Physics, Russian Academy of Sciences, Moscow, Russia; Research Institute of Physico-Chemical Medicine, Moscow, Russia; **Institute of Developmental Biology, Russian Academy of Sciences, Moscow, Russia; Institute of Biomedical Chemistry, Russian Academy of Medical Sciences, Moscow, Russia; and Assaf Harofeh Medical Center, Zerifin, Israel
| | - Alexey Kononikhin
- *Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, Russia; Kazan Federal University, Kazan, Republic of Tatarstan, Russia; Institute of Gene Biology, Russian Acedemy of Sciences, Moscow, Russia; Chemistry Department of Moscow State University, Moscow, Russia; Moscow Institute of Physics and Technology, Dolgoprudnyi, Russia; Institute for Energy Problems of Chemical Physics, Russian Academy of Sciences, Moscow, Russia; Research Institute of Physico-Chemical Medicine, Moscow, Russia; **Institute of Developmental Biology, Russian Academy of Sciences, Moscow, Russia; Institute of Biomedical Chemistry, Russian Academy of Medical Sciences, Moscow, Russia; and Assaf Harofeh Medical Center, Zerifin, Israel
| | - Sergey Kovalchuk
- *Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, Russia; Kazan Federal University, Kazan, Republic of Tatarstan, Russia; Institute of Gene Biology, Russian Acedemy of Sciences, Moscow, Russia; Chemistry Department of Moscow State University, Moscow, Russia; Moscow Institute of Physics and Technology, Dolgoprudnyi, Russia; Institute for Energy Problems of Chemical Physics, Russian Academy of Sciences, Moscow, Russia; Research Institute of Physico-Chemical Medicine, Moscow, Russia; **Institute of Developmental Biology, Russian Academy of Sciences, Moscow, Russia; Institute of Biomedical Chemistry, Russian Academy of Medical Sciences, Moscow, Russia; and Assaf Harofeh Medical Center, Zerifin, Israel
| | - Yelena Surina
- *Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, Russia; Kazan Federal University, Kazan, Republic of Tatarstan, Russia; Institute of Gene Biology, Russian Acedemy of Sciences, Moscow, Russia; Chemistry Department of Moscow State University, Moscow, Russia; Moscow Institute of Physics and Technology, Dolgoprudnyi, Russia; Institute for Energy Problems of Chemical Physics, Russian Academy of Sciences, Moscow, Russia; Research Institute of Physico-Chemical Medicine, Moscow, Russia; **Institute of Developmental Biology, Russian Academy of Sciences, Moscow, Russia; Institute of Biomedical Chemistry, Russian Academy of Medical Sciences, Moscow, Russia; and Assaf Harofeh Medical Center, Zerifin, Israel
| | - Ivan Smirnov
- *Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, Russia; Kazan Federal University, Kazan, Republic of Tatarstan, Russia; Institute of Gene Biology, Russian Acedemy of Sciences, Moscow, Russia; Chemistry Department of Moscow State University, Moscow, Russia; Moscow Institute of Physics and Technology, Dolgoprudnyi, Russia; Institute for Energy Problems of Chemical Physics, Russian Academy of Sciences, Moscow, Russia; Research Institute of Physico-Chemical Medicine, Moscow, Russia; **Institute of Developmental Biology, Russian Academy of Sciences, Moscow, Russia; Institute of Biomedical Chemistry, Russian Academy of Medical Sciences, Moscow, Russia; and Assaf Harofeh Medical Center, Zerifin, Israel
| | - Yakov Lomakin
- *Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, Russia; Kazan Federal University, Kazan, Republic of Tatarstan, Russia; Institute of Gene Biology, Russian Acedemy of Sciences, Moscow, Russia; Chemistry Department of Moscow State University, Moscow, Russia; Moscow Institute of Physics and Technology, Dolgoprudnyi, Russia; Institute for Energy Problems of Chemical Physics, Russian Academy of Sciences, Moscow, Russia; Research Institute of Physico-Chemical Medicine, Moscow, Russia; **Institute of Developmental Biology, Russian Academy of Sciences, Moscow, Russia; Institute of Biomedical Chemistry, Russian Academy of Medical Sciences, Moscow, Russia; and Assaf Harofeh Medical Center, Zerifin, Israel
| | - Anna Bacheva
- *Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, Russia; Kazan Federal University, Kazan, Republic of Tatarstan, Russia; Institute of Gene Biology, Russian Acedemy of Sciences, Moscow, Russia; Chemistry Department of Moscow State University, Moscow, Russia; Moscow Institute of Physics and Technology, Dolgoprudnyi, Russia; Institute for Energy Problems of Chemical Physics, Russian Academy of Sciences, Moscow, Russia; Research Institute of Physico-Chemical Medicine, Moscow, Russia; **Institute of Developmental Biology, Russian Academy of Sciences, Moscow, Russia; Institute of Biomedical Chemistry, Russian Academy of Medical Sciences, Moscow, Russia; and Assaf Harofeh Medical Center, Zerifin, Israel
| | - Alexey Stepanov
- *Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, Russia; Kazan Federal University, Kazan, Republic of Tatarstan, Russia; Institute of Gene Biology, Russian Acedemy of Sciences, Moscow, Russia; Chemistry Department of Moscow State University, Moscow, Russia; Moscow Institute of Physics and Technology, Dolgoprudnyi, Russia; Institute for Energy Problems of Chemical Physics, Russian Academy of Sciences, Moscow, Russia; Research Institute of Physico-Chemical Medicine, Moscow, Russia; **Institute of Developmental Biology, Russian Academy of Sciences, Moscow, Russia; Institute of Biomedical Chemistry, Russian Academy of Medical Sciences, Moscow, Russia; and Assaf Harofeh Medical Center, Zerifin, Israel
| | - Yaroslava Karpova
- *Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, Russia; Kazan Federal University, Kazan, Republic of Tatarstan, Russia; Institute of Gene Biology, Russian Acedemy of Sciences, Moscow, Russia; Chemistry Department of Moscow State University, Moscow, Russia; Moscow Institute of Physics and Technology, Dolgoprudnyi, Russia; Institute for Energy Problems of Chemical Physics, Russian Academy of Sciences, Moscow, Russia; Research Institute of Physico-Chemical Medicine, Moscow, Russia; **Institute of Developmental Biology, Russian Academy of Sciences, Moscow, Russia; Institute of Biomedical Chemistry, Russian Academy of Medical Sciences, Moscow, Russia; and Assaf Harofeh Medical Center, Zerifin, Israel
| | - Yulia Lyupina
- *Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, Russia; Kazan Federal University, Kazan, Republic of Tatarstan, Russia; Institute of Gene Biology, Russian Acedemy of Sciences, Moscow, Russia; Chemistry Department of Moscow State University, Moscow, Russia; Moscow Institute of Physics and Technology, Dolgoprudnyi, Russia; Institute for Energy Problems of Chemical Physics, Russian Academy of Sciences, Moscow, Russia; Research Institute of Physico-Chemical Medicine, Moscow, Russia; **Institute of Developmental Biology, Russian Academy of Sciences, Moscow, Russia; Institute of Biomedical Chemistry, Russian Academy of Medical Sciences, Moscow, Russia; and Assaf Harofeh Medical Center, Zerifin, Israel
| | - Oleg Kharybin
- *Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, Russia; Kazan Federal University, Kazan, Republic of Tatarstan, Russia; Institute of Gene Biology, Russian Acedemy of Sciences, Moscow, Russia; Chemistry Department of Moscow State University, Moscow, Russia; Moscow Institute of Physics and Technology, Dolgoprudnyi, Russia; Institute for Energy Problems of Chemical Physics, Russian Academy of Sciences, Moscow, Russia; Research Institute of Physico-Chemical Medicine, Moscow, Russia; **Institute of Developmental Biology, Russian Academy of Sciences, Moscow, Russia; Institute of Biomedical Chemistry, Russian Academy of Medical Sciences, Moscow, Russia; and Assaf Harofeh Medical Center, Zerifin, Israel
| | - Dobroslav Melamed
- *Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, Russia; Kazan Federal University, Kazan, Republic of Tatarstan, Russia; Institute of Gene Biology, Russian Acedemy of Sciences, Moscow, Russia; Chemistry Department of Moscow State University, Moscow, Russia; Moscow Institute of Physics and Technology, Dolgoprudnyi, Russia; Institute for Energy Problems of Chemical Physics, Russian Academy of Sciences, Moscow, Russia; Research Institute of Physico-Chemical Medicine, Moscow, Russia; **Institute of Developmental Biology, Russian Academy of Sciences, Moscow, Russia; Institute of Biomedical Chemistry, Russian Academy of Medical Sciences, Moscow, Russia; and Assaf Harofeh Medical Center, Zerifin, Israel
| | - Natalia Ponomarenko
- *Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, Russia; Kazan Federal University, Kazan, Republic of Tatarstan, Russia; Institute of Gene Biology, Russian Acedemy of Sciences, Moscow, Russia; Chemistry Department of Moscow State University, Moscow, Russia; Moscow Institute of Physics and Technology, Dolgoprudnyi, Russia; Institute for Energy Problems of Chemical Physics, Russian Academy of Sciences, Moscow, Russia; Research Institute of Physico-Chemical Medicine, Moscow, Russia; **Institute of Developmental Biology, Russian Academy of Sciences, Moscow, Russia; Institute of Biomedical Chemistry, Russian Academy of Medical Sciences, Moscow, Russia; and Assaf Harofeh Medical Center, Zerifin, Israel
| | - Natalia Sharova
- *Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, Russia; Kazan Federal University, Kazan, Republic of Tatarstan, Russia; Institute of Gene Biology, Russian Acedemy of Sciences, Moscow, Russia; Chemistry Department of Moscow State University, Moscow, Russia; Moscow Institute of Physics and Technology, Dolgoprudnyi, Russia; Institute for Energy Problems of Chemical Physics, Russian Academy of Sciences, Moscow, Russia; Research Institute of Physico-Chemical Medicine, Moscow, Russia; **Institute of Developmental Biology, Russian Academy of Sciences, Moscow, Russia; Institute of Biomedical Chemistry, Russian Academy of Medical Sciences, Moscow, Russia; and Assaf Harofeh Medical Center, Zerifin, Israel
| | - Eugene Nikolaev
- *Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, Russia; Kazan Federal University, Kazan, Republic of Tatarstan, Russia; Institute of Gene Biology, Russian Acedemy of Sciences, Moscow, Russia; Chemistry Department of Moscow State University, Moscow, Russia; Moscow Institute of Physics and Technology, Dolgoprudnyi, Russia; Institute for Energy Problems of Chemical Physics, Russian Academy of Sciences, Moscow, Russia; Research Institute of Physico-Chemical Medicine, Moscow, Russia; **Institute of Developmental Biology, Russian Academy of Sciences, Moscow, Russia; Institute of Biomedical Chemistry, Russian Academy of Medical Sciences, Moscow, Russia; and Assaf Harofeh Medical Center, Zerifin, Israel
| | - Alexander Gabibov
- *Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, Russia; Kazan Federal University, Kazan, Republic of Tatarstan, Russia; Institute of Gene Biology, Russian Acedemy of Sciences, Moscow, Russia; Chemistry Department of Moscow State University, Moscow, Russia; Moscow Institute of Physics and Technology, Dolgoprudnyi, Russia; Institute for Energy Problems of Chemical Physics, Russian Academy of Sciences, Moscow, Russia; Research Institute of Physico-Chemical Medicine, Moscow, Russia; **Institute of Developmental Biology, Russian Academy of Sciences, Moscow, Russia; Institute of Biomedical Chemistry, Russian Academy of Medical Sciences, Moscow, Russia; and Assaf Harofeh Medical Center, Zerifin, Israel
| |
Collapse
|
28
|
Mfuh AM, Larionov OV. Heterocyclic N-Oxides - An Emerging Class of Therapeutic Agents. Curr Med Chem 2015; 22:2819-57. [PMID: 26087764 PMCID: PMC4711945 DOI: 10.2174/0929867322666150619104007] [Citation(s) in RCA: 87] [Impact Index Per Article: 9.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/25/2015] [Revised: 05/22/2015] [Accepted: 06/18/2015] [Indexed: 11/22/2022]
Abstract
Heterocyclic N-oxides have emerged as potent compounds with anticancer, antibacterial, antihypertensive, antiparasitic, anti-HIV, anti-inflammatory, herbicidal, neuroprotective, and procognitive activities. The N-oxide motif has been successfully employed in a number of recent drug development projects. This review surveys the emergence of this scaffold in the mainstream medicinal chemistry with a focus on the discovery of the heterocyclic N-oxide drugs, N-oxide-specific mechanisms of action, drug-receptor interactions and synthetic avenues to these compounds. As the first review on this subject that covers the developments since 1950s to date, it is expected that it will inspire wider implementation of the heterocyclic N-oxide motif in the rational design of new medicinal agents.
Collapse
Affiliation(s)
| | - O V Larionov
- Department of Chemistry, University of Texas at San Antonio, One UTSA Circle, San Antonio, Texas, United States.
| |
Collapse
|
29
|
Marastoni M, Scotti A, Trapella C, Ferretti V, Sforza F, Gavioli R. Synthesis and activity of isoxazoline vinyl ester pseudopeptides as proteasome inhibitors. J Pept Sci 2014; 20:258-65. [PMID: 24677765 DOI: 10.1002/psc.2612] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/03/2013] [Revised: 12/03/2013] [Accepted: 12/09/2013] [Indexed: 11/07/2022]
Abstract
The ubiquitin–proteasome pathway (UPP) influences essential cellular functions including cell growth, differentiation, apoptosis, signal transduction, antigen processing and inflammatory responses. The main proteolytic component of the UPP is the 26S proteasome, which is responsible for the turnover of many cellular proteins and represents an attractive target for the treatment of pathologies such as cancer, as well as inflammatory, immune and neurodegenerative diseases. Natural and synthetic proteasome inhibitors having different chemical structures and potency have been discovered. We report herein the synthesis, proteasome inhibition and modelling studies of novel C-terminal isoxazoline vinyl ester pseudopeptides. Some new compounds that contain a C-terminal extended conjugation inhibit β1 and especially β5 proteasomal catalytic subunits with IC50 values ranging from 10 to 100 µm. These results will permit further optimization based on these structural moieties to develop more active and selective molecules.
Collapse
|
30
|
Voss C, Scholz C, Knorr S, Beck P, Stein ML, Zall A, Kuckelkorn U, Kloetzel PM, Groll M, Hamacher K, Schmidt B. α-Keto Phenylamides as P1′-Extended Proteasome Inhibitors. ChemMedChem 2014; 9:2557-64. [DOI: 10.1002/cmdc.201402244] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/12/2014] [Indexed: 12/14/2022]
|
31
|
Noel A, Delpech B, Crich D. Chemistry of the β-thiolactones: substituent and solvent effects on thermal decomposition and comparison with the β-lactones. J Org Chem 2014; 79:4068-77. [PMID: 24716459 DOI: 10.1021/jo500577c] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
Abstract
The synthesis of a series of di-, tri-, and tetraalkyl β-thiolactones and β-lactones is described as well as their thermal decomposition with extrusion of carbon oxysulfide and carbon dioxide in two solvents of opposite polarities. The β-thiolactones are considerably more thermally stable than the β-lactones and require higher temperatures for efficient decomposition in both solvents, whatever the degree of substitution. The results are interpreted in terms of a zwitterionic mechanism for fragmentation with a change in the rate-determining step between the two series.
Collapse
Affiliation(s)
- Amandine Noel
- Centre de Recherche de Gif, Institut de Chimie des Substances Naturelles, CNRS , Avenue de la Terrasse, 91190 Gif-sur-Yvette, France
| | | | | |
Collapse
|
32
|
Kawamura S, Unno Y, Asai A, Arisawa M, Shuto S. Development of a new class of proteasome inhibitors with an epoxyketone warhead: Rational hybridization of non-peptidic belactosin derivatives and peptide epoxyketones. Bioorg Med Chem 2014; 22:3091-5. [PMID: 24814885 DOI: 10.1016/j.bmc.2014.04.032] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/27/2014] [Revised: 04/15/2014] [Accepted: 04/15/2014] [Indexed: 01/18/2023]
Abstract
Proteasome inhibitors are currently a focus of increased attention as anticancer drug candidates. We recently performed systematic structure-activity relationship studies of the peptidic natural product belactosin A and identified non-peptidic derivative 2 as a highly potent proteasome inhibitor. However, the cell growth inhibitory effect of 2 is only moderate, probably due to the biologically unstable β-lactone warhead. Peptide epoxyketones are an important class of proteasome inhibitors exhibit high potency in cellular systems based on the efficient α,β-epoxyketone warhead. Importantly, belactosin derivatives bind primarily to the primed binding site, while peptide epoxyketones bind only to the non-primed binding site of proteasome, suggesting that hybridization of them might lead to the development of a new class of proteasome inhibitors. Thus, we successfully identified a novel chemotype of proteasome inhibitors 3 and 4 by rational structure-based design, which are expected to bind to both the primed and non-primed binding sites of proteasome.
Collapse
Affiliation(s)
- Shuhei Kawamura
- Faculty of Pharmaceutical Sciences, Hokkaido University, Kita-12, Nishi-6, Kita-ku, Sapporo 060-0812, Japan
| | - Yuka Unno
- Graduate School of Pharmaceutical Sciences, University of Shizuoka, Yada, Shizuoka 422-8526, Japan
| | - Akira Asai
- Graduate School of Pharmaceutical Sciences, University of Shizuoka, Yada, Shizuoka 422-8526, Japan
| | - Mitsuhiro Arisawa
- Graduate School of Pharmaceutical Sciences, Osaka University, 1-6 Yamada-oka, Suita, Osaka 565-0871, Japan
| | - Satoshi Shuto
- Faculty of Pharmaceutical Sciences, Hokkaido University, Kita-12, Nishi-6, Kita-ku, Sapporo 060-0812, Japan; Center for Research and Education on Drug Discovery, Hokkaido University, Kita-12, Nishi-6, Kita-ku, Sapporo 060-0812, Japan.
| |
Collapse
|
33
|
Micale N, Scarbaci K, Troiano V, Ettari R, Grasso S, Zappalà M. Peptide-Based Proteasome Inhibitors in Anticancer Drug Design. Med Res Rev 2014; 34:1001-69. [DOI: 10.1002/med.21312] [Citation(s) in RCA: 41] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Affiliation(s)
- Nicola Micale
- Dipartimento di Scienze del Farmaco e dei Prodotti per la Salute; Università degli Studi di Messina; Viale Annunziata 98168 Messina Italy
| | - Kety Scarbaci
- Dipartimento di Scienze del Farmaco e dei Prodotti per la Salute; Università degli Studi di Messina; Viale Annunziata 98168 Messina Italy
| | - Valeria Troiano
- Dipartimento di Scienze del Farmaco e dei Prodotti per la Salute; Università degli Studi di Messina; Viale Annunziata 98168 Messina Italy
| | - Roberta Ettari
- Dipartimento di Scienze Farmaceutiche; Università degli Studi di Milano; Via Mangiagalli 25 20133 Milano Italy
| | - Silvana Grasso
- Dipartimento di Scienze del Farmaco e dei Prodotti per la Salute; Università degli Studi di Messina; Viale Annunziata 98168 Messina Italy
| | - Maria Zappalà
- Dipartimento di Scienze del Farmaco e dei Prodotti per la Salute; Università degli Studi di Messina; Viale Annunziata 98168 Messina Italy
| |
Collapse
|
34
|
Kawamura S, Unno Y, Asai A, Arisawa M, Shuto S. Structurally Novel Highly Potent Proteasome Inhibitors Created by the Structure-Based Hybridization of Nonpeptidic Belactosin Derivatives and Peptide Boronates. J Med Chem 2014; 57:2726-35. [DOI: 10.1021/jm500045x] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Affiliation(s)
| | - Yuka Unno
- Graduate
School of Pharmaceutical Sciences, University of Shizuoka, Yada, Shizuoka 422-8526, Japan
| | - Akira Asai
- Graduate
School of Pharmaceutical Sciences, University of Shizuoka, Yada, Shizuoka 422-8526, Japan
| | - Mitsuhiro Arisawa
- Graduate
School of Pharmaceutical Sciences, Osaka University, 1-6 Yamada-oka, Suita, Osaka 565-0871, Japan
| | | |
Collapse
|
35
|
Sakae R, Matsuda N, Hirano K, Satoh T, Miura M. Highly Stereoselective Synthesis of (Borylmethyl)cyclopropylamines by Copper-Catalyzed Aminoboration of Methylenecyclopropanes. Org Lett 2014; 16:1228-31. [DOI: 10.1021/ol5001507] [Citation(s) in RCA: 80] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/23/2023]
Affiliation(s)
- Ryosuke Sakae
- Department
of Applied Chemistry,
Faculty of Engineering, Osaka University, Suita, Osaka 565-0871, Japan
| | - Naoki Matsuda
- Department
of Applied Chemistry,
Faculty of Engineering, Osaka University, Suita, Osaka 565-0871, Japan
| | - Koji Hirano
- Department
of Applied Chemistry,
Faculty of Engineering, Osaka University, Suita, Osaka 565-0871, Japan
| | - Tetsuya Satoh
- Department
of Applied Chemistry,
Faculty of Engineering, Osaka University, Suita, Osaka 565-0871, Japan
| | - Masahiro Miura
- Department
of Applied Chemistry,
Faculty of Engineering, Osaka University, Suita, Osaka 565-0871, Japan
| |
Collapse
|
36
|
Kawamura S, Unno Y, Hirokawa T, Asai A, Arisawa M, Shuto S. Rational hopping of a peptidic scaffold into non-peptidic scaffolds: structurally novel potent proteasome inhibitors derived from a natural product, belactosin A. Chem Commun (Camb) 2014; 50:2445-7. [DOI: 10.1039/c3cc48818g] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
Rational scaffold hopping of a natural product belactosin A derivative based on the pharmacophore model constructed resulted in the identification of the significantly simplified highly potent non-peptide derivatives.
Collapse
Affiliation(s)
- Shuhei Kawamura
- Faculty of Pharmaceutical Sciences
- Hokkaido University
- Kita-ku, Japan
| | - Yuka Unno
- Graduate School of Pharmaceutical Sciences
- University of Shizuoka
- Shizuoka 422-8526, Japan
| | - Takatsugu Hirokawa
- Molecular Profiling Research Center for Drug Discovery (MOLPROF)
- National Institute of Advanced Industrial Science and Technology (AIST)
- Tokyo 135-0064, Japan
| | - Akira Asai
- Graduate School of Pharmaceutical Sciences
- University of Shizuoka
- Shizuoka 422-8526, Japan
| | - Mitsuhiro Arisawa
- Graduate School of Pharmaceutical Sciences
- Osaka University
- Suita, Japan
| | - Satoshi Shuto
- Faculty of Pharmaceutical Sciences
- Hokkaido University
- Kita-ku, Japan
- Center for Research and Education on Drug Discovery
- Hokkaido University
| |
Collapse
|
37
|
Kawamura S, Unno Y, Tanaka M, Sasaki T, Yamano A, Hirokawa T, Kameda T, Asai A, Arisawa M, Shuto S. Investigation of the Noncovalent Binding Mode of Covalent Proteasome Inhibitors around the Transition State by Combined Use of Cyclopropylic Strain-Based Conformational Restriction and Computational Modeling. J Med Chem 2013; 56:5829-42. [DOI: 10.1021/jm400542h] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023]
Affiliation(s)
| | - Yuka Unno
- Graduate School of Pharmaceutical Sciences, University of Shizuoka, Yada, Shizuoka 422-8526, Japan
| | - Motohiro Tanaka
- School of Pharmacy, Aichi Gakuin University, 1-100 Kusumoto-cho, Chikusa-ku,
Nagoya 464-8650, Japan
| | - Takuma Sasaki
- School of Pharmacy, Aichi Gakuin University, 1-100 Kusumoto-cho, Chikusa-ku,
Nagoya 464-8650, Japan
| | - Akihito Yamano
- Rigaku Corporation, X-ray Institute, 3-9-12
Matsubara-cho, Akishima, Tokyo 196-8666, Japan
| | - Takatsugu Hirokawa
- Computational Biology Research Center (CBRC), National Institute of Advanced Industrial Science and Technology (AIST), 2-4-7 Aomi, Koutou-ku, Tokyo 135-0064, Japan
| | - Tomoshi Kameda
- Computational Biology Research Center (CBRC), National Institute of Advanced Industrial Science and Technology (AIST), 2-4-7 Aomi, Koutou-ku, Tokyo 135-0064, Japan
| | - Akira Asai
- Graduate School of Pharmaceutical Sciences, University of Shizuoka, Yada, Shizuoka 422-8526, Japan
| | | | | |
Collapse
|
38
|
Kawamura S, Unno Y, List A, Mizuno A, Tanaka M, Sasaki T, Arisawa M, Asai A, Groll M, Shuto S. Potent Proteasome Inhibitors Derived from the Unnatural cis-Cyclopropane Isomer of Belactosin A: Synthesis, Biological Activity, and Mode of Action. J Med Chem 2013; 56:3689-700. [DOI: 10.1021/jm4002296] [Citation(s) in RCA: 38] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/19/2023]
Affiliation(s)
- Shuhei Kawamura
- Faculty of
Pharmaceutical Sciences, Hokkaido University, Kita-12, Nishi-6, Kita-ku, Sapporo
060-0812, Japan
| | - Yuka Unno
- Graduate
School of Pharmaceutical
Sciences, University of Shizuoka, Yada,
Shizuoka 422-8526, Japan
| | - Anja List
- Center for Integrated Protein
Science at the Department of Chemistry, Chair of Biochemistry, Technische Universität München, Lichtenbergstrasse
4, 85747 Garching, Germany
| | - Akirai Mizuno
- Faculty of
Pharmaceutical Sciences, Hokkaido University, Kita-12, Nishi-6, Kita-ku, Sapporo
060-0812, Japan
| | - Motohiro Tanaka
- School of Pharmacy, Aichi Gakuin
University, 1-100 Kusumoto-cho, Chikusa-ku, Nagoya 464-8650, Japan
| | - Takuma Sasaki
- School of Pharmacy, Aichi Gakuin
University, 1-100 Kusumoto-cho, Chikusa-ku, Nagoya 464-8650, Japan
| | - Mitsuhiro Arisawa
- Faculty of
Pharmaceutical Sciences, Hokkaido University, Kita-12, Nishi-6, Kita-ku, Sapporo
060-0812, Japan
| | - Akira Asai
- Graduate
School of Pharmaceutical
Sciences, University of Shizuoka, Yada,
Shizuoka 422-8526, Japan
| | - Michael Groll
- Center for Integrated Protein
Science at the Department of Chemistry, Chair of Biochemistry, Technische Universität München, Lichtenbergstrasse
4, 85747 Garching, Germany
| | - Satoshi Shuto
- Faculty of
Pharmaceutical Sciences, Hokkaido University, Kita-12, Nishi-6, Kita-ku, Sapporo
060-0812, Japan
| |
Collapse
|
39
|
Proteasomal cleavage site prediction of protein antigen using BP neural network based on a new set of amino acid descriptor. J Mol Model 2013; 19:3045-52. [PMID: 23584554 DOI: 10.1007/s00894-013-1827-7] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/20/2012] [Accepted: 03/18/2013] [Indexed: 11/27/2022]
Abstract
The accurate identification of cytotoxic T lymphocyte epitopes is becoming increasingly important in peptide vaccine design. The ubiquitin-proteasome system plays a key role in processing and presenting major histocompatibility complex class I restricted epitopes by degrading the antigenic protein. To enhance the specificity and efficiency of epitope prediction and identification, the recognition mode between the ubiquitin-proteasome complex and the protein antigen must be considered. Hence, a model that accurately predicts proteasomal cleavage must be established. This study proposes a new set of parameters to characterize the cleavage window and uses a backpropagation neural network algorithm to build a model that accurately predicts proteasomal cleavage. The accuracy of the prediction model, which depends on the window sizes of the cleavage, reaches 95.454% for the N-terminus and 95.011% for the C-terminus. The results show that the identification of proteasomal cleavage sites depends on the sequence next to it and that the prediction performance of the C-terminus is better than that of the N-terminus on average. Thus, models based on the properties of amino acids can be highly reliable and reflect the structural features of interactions between proteasomes and peptide sequences.
Collapse
|
40
|
Hovhannisyan A, Pham TH, Bouvier D, Qin L, Melikyan G, Reboud-Ravaux M, Bouvier-Durand M. C1 and N5 derivatives of cerpegin: synthesis of a new series based on structure-activity relationships to optimize their inhibitory effect on 20S proteasome. Bioorg Med Chem Lett 2013; 23:2696-703. [PMID: 23541650 DOI: 10.1016/j.bmcl.2013.02.079] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/23/2012] [Revised: 02/15/2013] [Accepted: 02/18/2013] [Indexed: 11/25/2022]
Abstract
Thirty-two new derivatives of cerpegin (1,1,5-trimethylfuro[3,4-c]pyridine-3,4-dione) were designed and synthesized in high yield by a new method, combining several C(1) and N(5) substituents. All compounds were tested for their inhibitory effect on the CT-L, T-L and PA proteolytic activities of a purified mammalian 20S proteasome. Only one molecule inhibited both CT-L and PA activities. Sixteen molecules specifically inhibited PA at the micromolar range, out of which fourteen had IC50 values around 5 μM and two had IC50 values closer to 2 μM. Except in one case, neither calpain I nor cathepsin B was inhibited. In silico docking suggests a unique mode of binding of the most efficient compounds to the β1 catalytic site (PA activity) in relation to the chemical nature of C(1) substituents.
Collapse
Affiliation(s)
- Anna Hovhannisyan
- Department of Organic Chemistry, Yerevan State University, A. Manoogian Str. 1, 0025 Yerevan, Armenia.
| | | | | | | | | | | | | |
Collapse
|
41
|
Kawamura S, Unno Y, Asai A, Arisawa M, Shuto S. Design and synthesis of the stabilized analogs of belactosin A with the unnatural cis-cyclopropane structure. Org Biomol Chem 2013; 11:6615-22. [DOI: 10.1039/c3ob41338a] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
|
42
|
Guillaume B, Stroobant V, Bousquet-Dubouch MP, Colau D, Chapiro J, Parmentier N, Dalet A, Van den Eynde BJ. Analysis of the processing of seven human tumor antigens by intermediate proteasomes. THE JOURNAL OF IMMUNOLOGY 2012; 189:3538-47. [PMID: 22925930 DOI: 10.4049/jimmunol.1103213] [Citation(s) in RCA: 61] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/16/2023]
Abstract
We recently described two proteasome subtypes that are intermediate between the standard proteasome and the immunoproteasome. They contain only one (β5i) or two (β1i and β5i) of the three inducible catalytic subunits of the immunoproteasome. They are present in tumor cells and abundant in normal human tissues. We described two tumor antigenic peptides that are uniquely produced by these intermediate proteasomes. In this work, we studied the production by intermediate proteasomes of tumor antigenic peptides known to be produced exclusively by the immunoproteasome (MAGE-A3(114-122), MAGE-C2(42-50), MAGE-C2(336-344)) or the standard proteasome (Melan-A(26-35), tyrosinase(369-377), gp100(209-217)). We observed that intermediate proteasomes efficiently produced the former peptides, but not the latter. Two peptides from the first group were equally produced by both intermediate proteasomes, whereas MAGE-C2(336-344) was only produced by intermediate proteasome β1i-β5i. Those results explain the recognition of tumor cells devoid of immunoproteasome by CTL recognizing peptides not produced by the standard proteasome. We also describe a third antigenic peptide that is produced exclusively by an intermediate proteasome: peptide MAGE-C2(191-200) is produced only by intermediate proteasome β1i-β5i. Analyzing in vitro digests, we observed that the lack of production by a given proteasome usually results from destruction of the antigenic peptide by internal cleavage. Interestingly, we observed that the immunoproteasome and the intermediate proteasomes fail to cleave between hydrophobic residues, despite a higher chymotrypsin-like activity measured on fluorogenic substrates. Altogether, our results indicate that the repertoire of peptides produced by intermediate proteasomes largely matches the repertoire produced by the immunoproteasome, but also contains additional peptides.
Collapse
Affiliation(s)
- Benoît Guillaume
- Ludwig Institute for Cancer Research, Brussels Branch, B-1200 Brussels, Belgium
| | | | | | | | | | | | | | | |
Collapse
|
43
|
Kisselev AF, van der Linden WA, Overkleeft HS. Proteasome inhibitors: an expanding army attacking a unique target. ACTA ACUST UNITED AC 2012; 19:99-115. [PMID: 22284358 DOI: 10.1016/j.chembiol.2012.01.003] [Citation(s) in RCA: 404] [Impact Index Per Article: 33.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/02/2011] [Revised: 01/09/2012] [Accepted: 01/09/2012] [Indexed: 12/30/2022]
Abstract
Proteasomes are large, multisubunit proteolytic complexes presenting multiple targets for therapeutic intervention. The 26S proteasome consists of a 20S proteolytic core and one or two 19S regulatory particles. The 20S core contains three types of active sites. Many structurally diverse inhibitors of these active sites, both natural product and synthetic, have been discovered in the last two decades. One, bortezomib, is used clinically for treatment of multiple myeloma, mantle cell lymphoma, and acute allograft rejection. Five more recently developed proteasome inhibitors are in trials for treatment of myeloma and other cancers. Proteasome inhibitors also have activity in animal models of autoimmune and inflammatory diseases, reperfusion injury, promote bone and hair growth, and can potentially be used as anti-infectives. In addition, inhibitors of ATPases and deubiquitinases of 19S regulatory particles have been discovered in the last decade.
Collapse
Affiliation(s)
- Alexei F Kisselev
- Department of Pharmacology and Toxicology, Norris Cotton Cancer Center, Dartmouth Medical School, Lebanon, NH 03756, USA.
| | | | | |
Collapse
|
44
|
de Meijere A, Korotkov VS, Lygin AV, Larionov OV, Sokolov VV, Graef T, Es-Sayed M. Synthesis and biological activity of simplified belactosin C analogues. Org Biomol Chem 2012; 10:6363-74. [DOI: 10.1039/c2ob25586c] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
|
45
|
Gräwert MA, Groll M. Exploiting nature's rich source of proteasome inhibitors as starting points in drug development. Chem Commun (Camb) 2011; 48:1364-78. [PMID: 22039589 DOI: 10.1039/c1cc15273d] [Citation(s) in RCA: 54] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Abstract
Cancer is the No. 2 cause of death in the Western world and one of the most expensive diseases to treat. Thus, it is not surprising, that every major pharmaceutical and biotechnology company has a blockbuster oncology product. In 2003, Millennium Pharmaceuticals entered the race with Velcade®, a first-in-class proteasome inhibitor that has been approved by the FDA for treatment of multiple myeloma and its sales have passed the billion dollar mark. Velcade®'s extremely toxic boronic acid pharmacophore, however, contributes to a number of severe side effects. Nevertheless, the launching of this product has validated the proteasome as a target in fighting cancer and further proteasome inhibitors have entered the market as anti-cancer drugs. Additionally, proteasome inhibitors have found application as crop protection agents, anti-parasitics, immunosuppressives, as well as in new therapies for muscular dystrophies and inflammation. Many of these compounds are based on microbial metabolites. In this review, we emphasize the important role of the structural elucidation of the various unique binding mechanisms of these compounds that have been optimized throughout evolution to target the proteasome. Based on this knowledge, medicinal chemists have further optimized these natural products, resulting in potential drugs with reduced off-target activities.
Collapse
Affiliation(s)
- Melissa Ann Gräwert
- Center for Integrated Protein Science at the Department Chemie, Lehrstuhl für Biochemie, Technische Universität München, Lichtenbergstrasse 4, 85748 Garching, Germany.
| | | |
Collapse
|
46
|
Synthesis and SAR study of novel peptide aldehydes as inhibitors of 20S proteasome. Molecules 2011; 16:7551-64. [PMID: 21894088 PMCID: PMC6264673 DOI: 10.3390/molecules16097551] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/01/2011] [Revised: 08/29/2011] [Accepted: 08/30/2011] [Indexed: 02/06/2023] Open
Abstract
Based on the analysis of the crystal structure of MG101 (1) and 20S proteasomes, a new series of peptide aldehyde derivatives were designed and synthesized. Their ability to inhibit 20S proteasome was assayed. Among them, Cbz-Glu(OtBu)-Phe-Leucinal (3c), Cbz-Glu(OtBu)-Leu-Leucinal (3d), and Boc-Ser(OBzl)-Leu-Leucinal (3o) exhibited the most activity, which represented an order of magnitude enhancement compared with MG132 (2). The covalent docking protocol was used to explore the binding mode. The structure-activity relationship of the peptide aldehyde inhibitors is discussed.
Collapse
|
47
|
Korotkov VS, Ludwig A, Larionov OV, Lygin AV, Groll M, de Meijere A. Synthesis and biological activity of optimized belactosin C congeners. Org Biomol Chem 2011; 9:7791-8. [DOI: 10.1039/c1ob05661a] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
|
48
|
Aubry S, Sasaki K, Eloy L, Aubert G, Retailleau P, Cresteil T, Crich D. Exploring the potential of the β-thiolactones in bioorganic chemistry. Org Biomol Chem 2011; 9:7134-43. [DOI: 10.1039/c1ob05967j] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
|
49
|
Bazzaro M, Anchoori RK, Mudiam MKR, Issaenko O, Kumar S, Karanam B, Lin Z, Isaksson Vogel R, Gavioli R, Destro F, Ferretti V, Roden RBS, Khan SR. α,β-Unsaturated carbonyl system of chalcone-based derivatives is responsible for broad inhibition of proteasomal activity and preferential killing of human papilloma virus (HPV) positive cervical cancer cells. J Med Chem 2010; 54:449-56. [PMID: 21186794 DOI: 10.1021/jm100589p] [Citation(s) in RCA: 66] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Abstract
Proteasome inhibitors have potential for the treatment of cervical cancer. We describe the synthesis and biological characterization of a new series of 1,3-diphenylpropen-1-one (chalcone) based derivatives lacking the boronic acid moieties of the previously reported chalcone-based proteasome inhibitor 3,5-bis(4-boronic acid benzylidene)-1-methylpiperidin-4-one and bearing a variety of amino acid substitutions on the amino group of the 4-piperidone. Our lead compound 2 (RA-1) inhibits proteasomal activity and has improved dose-dependent antiproliferative and proapoptotic properties in cervical cancer cells containing human papillomavirus. Further, it induces synergistic killing of cervical cancer cell lines when tested in combination with an FDA approved proteasome inhibitor. Exploration of the potential mechanism of proteasomal inhibition by our lead compound using in silico docking studies suggests that the carbonyl group of its oxopiperidine moiety is susceptible to nucleophilic attack by the γ-hydroxythreonine side chain within the catalytic sites of the proteasome.
Collapse
Affiliation(s)
- Martina Bazzaro
- Masonic Cancer Center and Department of Obstetrics, Gynecology and Women's Heath, University of Minnesota Twin Cities, Minneapolis, Minnesota 55455, United States.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
50
|
de Meijere A, Chaplinski V, Winsel H, Kordes M, Stecker B, Gazizova V, Savchenko AI, Boese R, Schill née Brackmann F. Cyclopropylamines from N,N-Dialkylcarboxamides and Grignard Reagents in the Presence of Titanium Tetraisopropoxide or Methyltitanium Triisopropoxide. Chemistry 2010; 16:13862-75. [DOI: 10.1002/chem.201001550] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
|